Chimerix Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix or view top-rated stocks.

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chimerix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chimerix.

Chimerix, Inc. (NASDAQ:CMRX) posted its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. Chimerix had a negative trailing twelve-month return on equity of 54.11% and a negative net margin of 3,035.43%.
View Chimerix's earnings history.

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CMRX shares have increased by 341.0% and is now trading at $6.35.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued 12-month target prices for Chimerix's shares. Their forecasts range from $14.00 to $21.00. On average, they anticipate Chimerix's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 199.2% from the stock's current price.
View analysts' price targets for Chimerix or view top-rated stocks among Wall Street analysts.

Some companies that are related to Chimerix include Nuvation Bio (NUVB), Atea Pharmaceuticals (AVIR), Harmony Biosciences (HRMY), Indivior (INVVY), Myovant Sciences (MYOV), Amarin (AMRN), Organogenesis (ORGO), Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Revance Therapeutics (RVNC), ADC Therapeutics (ADCT), Cassava Sciences (SAVA), Deciphera Pharmaceuticals (DCPH), NGM Biopharmaceuticals (NGM) and Trillium Therapeutics (TRIL).
View all of CMRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.75%), Opaleye Management Inc. (5.37%), Vanguard Group Inc. (4.16%), State Street Corp (3.73%), Point72 Asset Management L.P. (3.69%) and Renaissance Technologies LLC (2.90%). Company insiders that own Chimerix stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Renaissance Technologies LLC, Invesco Ltd., Acuta Capital Partners LLC, Ikarian Capital LLC, Price T Rowe Associates Inc. MD, and Russell Investments Group Ltd..
View insider buying and selling activity for Chimerix or view top insider-selling stocks.

CMRX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., State Street Corp, Northern Trust Corp, Cambiar Investors LLC, Nuveen Asset Management LLC, Swiss National Bank, and Integral Health Asset Management LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix or or view top insider-buying stocks.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CMRX stock can currently be purchased for approximately $6.35.

Chimerix has a market capitalization of $547.69 million and generates $5.37 million in revenue each year. The biopharmaceutical company earns $-43,520,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

Chimerix employs 54 workers across the globe.

The official website for Chimerix is www.chimerix.com.

Chimerix is headquartered at 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at (919) 806-1074 or via email at [email protected].